HPV vaccination after treatment of cervical intraepithelial neoplasia (CIN/HSIL)

Background Human papillomavirus (HPV) vaccination can reliably protect against the development of cervical cancer and its precursors. Whether adjuvant HPV vaccination can reduce the recurrence rate after therapy is not yet fully understood. Objectives Can a benefit for adjuvant HPV vaccination be proven from the existing data? Methods Evaluation and comparative summary of three current meta-analyses of adjuvant HPV vaccination after surgical therapy of cervical intraepithelial neoplasia (CIN). Results Three meta-analyses consistently prove that the recurrence rate can be reduced by around 65% by means of adjuvant HPV vaccination after surgical therapy of a CIN. Approximately 2-3% of women vaccinated adjuvantly benefit from vaccination. The number needed to vaccinate is approximately 46. Conclusion Adjuvant HPV vaccination may be recommended.